DMAb-1 / DMAb-2

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a U.S.-based clinical-stage biotech focused on developing DNA-based immunotherapies and vaccines. Its core strategy leverages a proprietary two-part platform—SynCon® for plasmid design and CELLECTRA® for delivery—to advance a pipeline targeting HPV-related diseases, cancer, and infectious diseases. The company's most significant near-term catalyst is the FDA review of its Biologics License Application (BLA) for INO-3107 in recurrent respiratory papillomatosis (RRP), which represents a potential first-in-class DNA medicine approval. With a seasoned leadership team and a history of strategic partnerships, Inovio is positioning itself at the forefront of nucleic acid therapeutics.

Therapeutic Areas

Other Prevention of COVID-19 Drugs